VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI; Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, MI.
Clin Genitourin Cancer. 2024 Dec;22(6):102201. doi: 10.1016/j.clgc.2024.102201. Epub 2024 Aug 13.
Studies comparing radical prostatectomy (RP) to radiation therapy (RT) have consistently shown that patients undergoing RT have a higher risk of other-cause mortality (OCM) compared to RP, signifying poor health status of the former patients. We aimed to evaluate the impact of RP versus RT on cancer-specific mortality (CSM) over a cohort with equivalent OCM risk.
The SEER database was queried to identify patients with nonmetastatic PCa between 2004 and 2009. Patients were matched based on their calculated 10-year OCM risk and further stratified for D'Amico Risk Score and Gleason Grade. A Cox-regression model was used to calculate the 10-year OCM risk. Propensity-score based on the calculated OCM risk were used to match RP and RT patients. Cumulative incidence curves and Competing-risk regression analyses were used to examine the impact of treatment on CSM in the matched cohort.
We identified 55,106 PCa patients treated with RP and 36,674 treated with RT. After match, 6,506 patients were equally distributed for RT versus RP, with no difference in OCM rates (P = .2). The 10-year CSM rates were 8.8% versus 0.6% (P = .01) for RT versus RP in patients with unfavorable-intermediate-risk (Gleason Score 4 + 3) and 7.9% versus 3.9% (P = .003) for high-risk disease. There was no difference in CSM among RT and RP patients for favorable-intermediate-risk (Gleason Score 3 + 4) and low-risk disease.
In a matched cohort of PCa patients with comparable OCM between the 2 arms, RP yielded a more favorable CSM rate compared to RT only for unfavorable-intermediate- and high-risk groups.
比较根治性前列腺切除术(RP)和放射治疗(RT)的研究一致表明,与 RP 相比,接受 RT 的患者发生其他原因死亡率(OCM)的风险更高,这表明前者患者的健康状况较差。我们旨在评估 RP 与 RT 对具有相当 OCM 风险的患者队列中癌症特异性死亡率(CSM)的影响。
在 2004 年至 2009 年间,SEER 数据库被查询以确定患有非转移性前列腺癌的患者。患者根据其计算的 10 年 OCM 风险进行匹配,并进一步根据 D'Amico 风险评分和 Gleason 分级进行分层。Cox 回归模型用于计算 10 年 OCM 风险。基于计算出的 OCM 风险的倾向评分用于匹配 RP 和 RT 患者。累积发病率曲线和竞争风险回归分析用于检查匹配队列中治疗对 CSM 的影响。
我们确定了 55106 例接受 RP 治疗的前列腺癌患者和 36674 例接受 RT 治疗的患者。匹配后,6506 例患者在 RT 与 RP 之间均匀分布,OCM 发生率无差异(P =.2)。对于不利中间风险(Gleason 评分 4 + 3)的患者,10 年 CSM 率分别为 8.8%与 0.6%(P =.01),对于高危疾病,10 年 CSM 率分别为 7.9%与 3.9%(P =.003)。对于有利中间风险(Gleason 评分 3 + 4)和低危疾病的患者,RT 与 RP 之间的 CSM 无差异。
在 2 组间 OCM 相似的 PCa 患者匹配队列中,与 RT 相比,RP 仅在不利中间风险和高危组中产生更有利的 CSM 率。